DBV Technologies (NASDAQ:DBVT) Stock Price Down 7.1% – What’s Next?

DBV Technologies S.A. (NASDAQ:DBVT) dropped 7.1% on Thursday. The stock traded as low as $11.39 and last traded at $11.3110. 224,641 shares traded hands during trading, a decline of 25% from the average daily volume of 300,439 shares. The stock had previously closed at $12.17.

Analysts Set New Price Targets

A number of brokerages have recently commented on DBVT. Citizens Jmp lifted their price target on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a report on Tuesday, June 30th. HC Wainwright reiterated a “buy” rating on shares of DBV Technologies in a report on Tuesday, June 30th. Weiss Ratings downgraded DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 17th. Wall Street Zen lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of DBV Technologies in a research note on Thursday, September 10th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $48.50.

DBV Technologies Price Performance

The company has a 50 day simple moving average of $13.51 and a 200-day simple moving average of $16.89. The stock has a market capitalization of $726.89 million, a P/E ratio of -3.29 and a beta of -0.95.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Elmind Capital LP purchased a new stake in shares of DBV Technologies in the 1st quarter valued at about $5,536,000. Perceptive Advisors LLC bought a new stake in DBV Technologies during the first quarter worth about $20,146,000. Dorsey Wright & Associates bought a new position in shares of DBV Technologies during the 1st quarter valued at about $2,142,000. Diversify Wealth Management LLC purchased a new position in shares of DBV Technologies during the 1st quarter valued at about $1,293,000. Finally, Vivo Capital LLC grew its position in DBV Technologies by 8.4% during the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after acquiring an additional 205,943 shares during the last quarter. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s lead technology, Viaskin, is designed to deliver targeted immunotherapy through the skin without requiring an injection. Its approach is intended to expose the immune system to controlled amounts of an allergen while limiting systemic exposure.

DBV Technologies’ primary product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.